Advances in inhaled antibiotics for management of respiratory tract infections.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
31
3
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
The incidence of bacterial respiratory tract infections is growing. In a context of increasing antibiotic resistance and lack of new classes of antibiotics, inhaled antibiotics emerge as a promising therapeutic strategy. Although they are generally used for cystic fibrosis, their use in other conditions is becoming more frequent, including no-cystic fibrosis bronchiectasis, pneumonia and mycobacterial infections. Inhaled antibiotics exert beneficial microbiological effects in bronchiectasis and chronic bronchial infection. In nosocomial and ventilator-associated pneumonia, aerosolized antibiotics improve cure rates and bacterial eradication. In refractory Mycobacterium avium complex infections, amikacin liposome inhalation suspension is more effective in achieving long-lasting sputum conversion. In relation to biological inhaled antibiotics (antimicrobial peptides, interfering RNA and bacteriophages), currently in development, there is no still enough evidence that support their use in clinical practice. The effective antimicrobiological activity of inhaled antibiotics, added to their potential to overcoming resistances to systemic antibiotics, make inhaled antibiotics a plausible alternative.
Identifiants
pubmed: 36866728
doi: 10.1097/MCP.0000000000000952
pii: 00063198-202305000-00006
doi:
Substances chimiques
Anti-Bacterial Agents
0
Amikacin
84319SGC3C
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
160-167Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
GBC 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396:1223–1249.
Global action plan on antimicrobial resistance. https://www.who.int/publications/i/item/9789241509763 [Accessed 28 February 2023]
Southwell N. Inhaled penicillin in bronchial infections. Lancet 1946; 2:225–227.
Taccetti G, Francalanci M, Pizzamiglio G, et al. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics 2021; 10:338.
Martin AR, Finlay W. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv 2015; 12:889–900.
Máiz L, Blanco-Aparicio M. New inhaled antibiotics and forms of administration. Open Respir Arch 2020; 2:251–264.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanosc Res Lett 2013; 8:102.
Bassetti M, Vena A, Russo A, et al. Inhaled liposomal antimicrobial delivery in lung infections. Drugs 2020; 80:1309–1318.
Nisini R, Poerio N, Mariotti S, et al. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol 2018; 9:155.
Huang Z, Klodizinska SN, Wan F, et al. Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Deliv Transl Res 2021; 11:1634–1654.
Forier K, Messiaen AS, Raemdonck K, et al. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicina 2013; 8:935–949.
Shiehzadeh F, Tafaghodi M. Dry powder form of polymeric nanoparticles for pulmonary drug delivery. Curr Pharm Des 2016; 17:2549–2560.
Derbali RM, Aoun V, Moussa G, et al. Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study. Mol Pharm 2019; 16:1906–1916.
Patel KK, Tripathi M, Pandey N, et al. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilms associated mucoid P. aeruginosa infection in cystic fibrosis. Int J Pharm 2019; 563:30–42.
Scolari IR, Páez PL, Sánchez-Borzone ME, Granero GE. Promising chitosan-coated alginate-tween 80 nanoparticles as rifampicin coadministered ascorbic acid delivery carrier against Mycobacterium tuberculosis. AAPS PharmSciTech 2019; 20:67.
Wan F, Bohr SSR, Klodzinska SN, et al. Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into Pseudomonas aeruginosa biofilms in lungs. ACS Appl Mater Interfaces 2020; 12:380–389.
Klodzinska SN, Wan F, Jumaa H, et al. Utilizing nanoparticles for improving antibiofilm effects of azythromycin: a head-to-head comparison of modified hyaluronic acid nanogels and coated poly (lactic-co-glycolic acid) nanoparticles. J Colloid Interface Sci 2019; 555:595–606.
Cheow WS, Chang MW, Hadinoto K. The roles of lipid in antibiofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surfaces A Physicochem Eng Aspects 2011; 389:158–165.
Lee HW, Kharel S, Loo SCJ. Lipid-coated hybrid nanoparticles for enhanced bacterial biofilm penetration and antibiofilm efficacy. ACS Omega 2022; 7:35814–35824.
Solarat B, Perea L, Faner R, et al. Pathophysiology of chronic bronchial infection in bronchiectasis. Arch Bronconeumol 2022; S0300-2896:00525–527.
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50:1700629.
Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med 2019; 7:855–869.
Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189:975–982.
Spencer S, Donovan T, Chalmers JD, et al. Intermittent prophylactic antibiotics for bronchiectasis. Cochrane Database Syst Rev 2022; 5:CD013254.
De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in noncystic fibrosis bronchiectasis. Eur Respir J 2018; 51:1702052.
Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in noncystic fibrosis bronchiectasis. Eur Respir J 2018; 51:1702053.
Donovan T, Felix LM, Chalmers JD, et al. Continuous versus intermittent antibiotics for bronchiectasis. Cochrane Database SystRev 2018; 6:CD012733.
Flume PA, VanDevanter DR, Morgan EE, et al. A phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros 2016; 15:495–502.
VanDevanter DR, Pasta DJ, Konstan MW. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2015; 14:763–769.
Schwarz C, Grehn C, Temming S, et al. Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. J Cyst Fibros 2021; 20:1035–1039.
Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions. N Engl J Med 2014; 370:341–351.
Heffernan AJ, Sime FB, Lipman J, et al. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. Int J Antimicrob Agents 2019; 53:234–245.
Póvoa FCC, Cardinal-Fernández P, Silva-Maia I, et al. Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. J Crit Care 2018; 43:240–245.
Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184:106–115.
Tulli G, Messori A, Trippoli S, Marinai C. Noninferiority of colistin compared with standard care for the treatment of ventilator-associated pneumonia. Int J Antimicrob Agents 2017; 49:638–641.
Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest 2017; 151:1239–1246.
Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis 2020; 20:330–340.
Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007; 60:1216–1226.
Solé-Lleonart C, Rouby JJ, Blot S, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults. Anesthesiology 2017; 126:890–908.
Hassan NA, Awdallah FF, Abbassi MM, Sabry NA. Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controller trial. Crit Care Med 2018; 46:45–52.
Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care 2016; 6:26.
Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015; 43:527–533.
Tang R, Luo R, Wu B, et al. Effectiveness and safety of adjuntive inhaled antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Crit Care 2021; 65:133–139.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61–e111.
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del tórax (ALAT). Eur Respir J 2017; 50:1700582.
Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a larges U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc 2020; 17:178–185.
Miller JB, Abramson HA, Ratner B. Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children. Am J Dis Child 1950; 80:207–237.
Nainwal N, Sharma Y, Jakhmola V. Dry powder inhalers of antitubercular drugs. Tuberculosis 2022; 135:102228.
Dharmadhikari AS, Kabadi M, Gerety B, et al. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approacho to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemoter 2013; 57:2613–2619.
Srichana T, Ratanajamit C, Juthong S, et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs. Biol Pharm Bull 2016; 39:1815–1822.
Laohapojanart N, Ratanajamit C, Kawkitinarong K, Srichana T. Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: a randomized controlled trial. Pulm Pharmacol Ther 2021; 70:102056.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 2020; 71:e1–e36.
Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med 2018; 198:1559–1569.
Winthrop KL, Flume PA, Thomson R, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease. A 12-month open-label extension clinical trial. Ann Am Thorac Soc 2021; 18:1147–1157.
Griffith DE, Thomson R, Flume PA, et al. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease. Sustainability and durability of culture conversion and safety of long-term exposure. Chest 2021; 160:831–842.
Henriette-Zweijpfenning SM, Chiron R, Essink S, et al. Safety and outcomes of amikacin liposome inhalation suspension for mycobacterium abscessus pulmonary disease: a NTM-NET study. Chest 2022; 162:76–81.
León-Buitimea A, Garza-Cárdenas CR, Garza-Cervantes JA, et al. The demand for new antibiotics: antimicrobial peptides, nanoparticles, and combinatorial therapies as future strategies in antibacterial agent design. Front Microbiol 2020; 11:1669.
Li J, Zheng H, Leung SSY. Pulmonary delivery of emerging antibacterials for bacterial lung infections treatment. Pharm Res 2022; 19:1–16.
Wang Y, Chang RYK, Britton WJ, Chan HK. Advances in the development of antimicrobial peptides and proteins for inhaled therapy. Adv Drug Deliv Rev 2022; 180:114066.
Van Eijk M, van Dijk A, van der Ent CK, et al. PepBiotics, novel cathelicidin-inspired antimicrobials to fight pulmonary bacterial infections. Biochim Biophys Acta Gen Subj 2021; 1865:129951.
Chang RYK, Wallin M, Lin Y, et al. Phage therapy for respiratory infections. Adv Drug Deliv Rev 2018; 133:76–86.
Lebeaux D, Merabishvili M, Caudron E, et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses 2021; 13:60.
Chaudhry WN, Concepción-Acevedo J, Park T, et al. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 2017; 12:e0168615.
Kamal F, Dennis JJ. Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity. Appl Environ Microbiol 2015; 81:1132–1138.